Abstract:Dysfunctional B-cell-activating factor (BAFF) system is related to many autoimmune diseases. The regulatory functions of BAFF/BAFF receptors were investigated in an in vitro coculture system. Different regulatory roles of BAFF were investigated via different receptors in immune thrombocytopenia. The upregulated BAFF receptors on autoreactive lymphocytes lead to their hypersensitivity to BAFF.Summary Background The pathogenesis of immune thrombocytopenia (ITP) remains enigmatic. B-cell-activating factor (BAFF) and its receptors (BAFF receptor [BAFF-R], transmembrane activator and calcium modulator and cyclophilin ligand interactor [TACI], and B-cell maturation antigen) play central roles in the integrated homeostatic regulation of lymphocytes.Objectives To investigate the pathologic roles of BAFF receptors in regulating the bioactivities of lymphocytes in ITP.Methods An in vitro culture system was established by stimulating CD14(-) peripheral lymphocytes with platelet-preloaded dendritic cells in the presence of recombinant human BAFF (rhBAFF; 20 ng mL(-1)). The functions of BAFF receptors were specifically blocked with blocking antibodies.Results BAFF-R, besides prolonging the survival of B cells in both patients and healthy controls, prominently promoted the survival of CD8(+) T cells and the proliferation of B cells in patients with ITP. TACI, as a positive regulator, not only promoted the proliferation of CD4(+) and CD8(+) T cells, but also significantly enhanced the secretion of interleukin-4 in patients with ITP, but not in controls. Besides revealing the pathologic roles of BAFF receptors, these results also indicate that lymphocytes of patients with ITP have enhanced antiapoptotic or proliferative capacity as compared with those from healthy controls when exposed under similar stimulation of rhBAFF. Further study demonstrated that activated autoreactive B cells and CD4(+) T cells from patients with ITP showed significantly higher expression of BAFF-R or TACI than those from healthy controls.Conclusions Both BAFF-R and TACI are pathogenic participants in ITP. Their dysregulated expression in patients with ITP may lead to hyperreactivity of activated autoreactive lymphocytes in response to rhBAFF, and thus is highly significant in the pathogenesis of ITP.

The role of BAFF and BAFF-R inhibitors in the treatment of immune thrombocytopenia; a focused review

Novel treatments for immune thrombocytopenia: targeting platelet autoantibodies

The Effects Of Baff And Baff-R-Fc Fusion Protein In Immune Thrombocytopenia

Immune Thrombocytopenia and B-Cell-Activating Factor/A Proliferation-Inducing Ligand

Translating mechanisms into therapeutic strategies for immune thrombocytopenia (ITP): Lessons from clinical trials

Novel therapeutics and future directions for refractory immune thrombocytopenia

[Reaserch Advances in the Treatment of Primary Immune Thrombocytopenia--Review].

Investigational drugs for immune thrombocytopenia

Classificatory Treatment of Refractory Idiopathic Thrombocytopenic Purpura

B cells and antibodies in refractory immune thrombocytopenia

Neutrophils Contribute to Elevated BAFF Levels to Modulate Adaptive Immunity in Patients with Primary Immune Thrombocytopenia by CD62P and PSGL1 Interaction

Participation of B‐cell‐activating Factor Receptors in the Pathogenesis of Immune Thrombocytopenia

BAFF - an essential survival factor for B cells: Links to genesis of ITP and may be of therapeutic target.

A Review of Pathogenesis and Treatment Options

Primary Immune Thrombocytopenia: Novel Insights into Pathophysiology and Disease Management

Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives

Current therapeutic strategies and perspectives in refractory ITP: What have we learned recently?

Immune thrombocytopenia: a review on the pathogenetic role of immune cells

Novel therapies for immune thrombocytopenia

Recent progress in ITP treatment

Current treatment options for primary immune thrombocytopenia